C&EN White Paper >> Minimizing Risk in API & Drug Product Development & Manufacturing

Nov 03, 2016
C&EN White Paper >>

Minimizing Risk in API & Drug Product Development
& Manufacturing >> A Fully Integrated Supply Chain

Brought to you by CordenPharma

 


Overview
 
The pharmaceutical and biopharma industry continues to experience solid growth in an expanding global market. This market growth has been accompanied by an ever-changing industry landscape, with consolidation among long-time "big pharma" leaders, ongoing mergers and acquisitions, and the emergence of start-ups and technology-based offshoots from academic laboratories. As the industry continuously adapts to evolving market pressures -- whether medical, economic, or demographic in nature--the trend toward outsourcing of Active Pharmaceutical Ingredient (API) & Drug Product (DP) manufacturing to (Contract Manufacturing Organizations) CMOs with specialized capabilities, expertise and infrastructure remains a strong one.
 

Key learning objectives
 
   >> Understand the
challenges faced by the biopharma &
pharma industry
 
  >> Learn the needs faced in market sectors:   
  • Peptides, Lipids, Carbohydrates & Oligonucleotides
  • Highly Potent
    & Oncology
  • Injectables
  • Small Molecules 
  • Antibiotics 
  >> Understand the         advantages of having a fully-integrated global supply chain partner
 
         >> Learn the value of   having CordenPharma as your CDMO: Greater security, quality compliance, and time
& cost efficiency

Brought to you by: